BackAgomAb Therapeutics N.V. American Depositary Shares Overview

AgomAb Therapeutics N.V. American Depositary Shares Other Liabilities

Latest other liabilities for AGMB: $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

AgomAb Therapeutics N.V. American Depositary Shares Other Liabilities History

Loading

AgomAb Therapeutics N.V. American Depositary Shares vs. peers: Other Liabilities Comparison

Loading

AgomAb Therapeutics N.V. American Depositary Shares Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) FAQ

As of the most recent data (December 2025), AGMB shows a other liabilities of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AGMB's other liabilities is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether AgomAb Therapeutics N.V. American Depositary Shares is outperforming or lagging.

Tracking AGMB's other liabilities over time shows whether AgomAb Therapeutics N.V. American Depositary Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other liabilities page, Stockcircle has AgomAb Therapeutics N.V. American Depositary Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other liabilities (currently $0) with ownership activity and broader fundamentals.

AgomAb Therapeutics N.V. American Depositary Shares's other liabilities is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.